T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.

Hepatocellular Carcinoma PD-1 T-cell exhaustion immune checkpoint blockade immune profiling mass cytometry tissue-resident memory T cells

Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
08 2022
Historique:
received: 07 08 2021
revised: 16 02 2022
accepted: 28 02 2022
pubmed: 4 4 2022
medline: 22 7 2022
entrez: 3 4 2022
Statut: ppublish

Résumé

Despite recent translation of immunotherapies into clinical practice, the immunobiology of hepatocellular carcinoma (HCC), in particular the role and clinical relevance of exhausted and liver-resident T cells remain unclear. We therefore dissected the landscape of exhausted and resident T cell responses in the peripheral blood and tumor microenvironment of patients with HCC. Lymphocytes were isolated from the blood, tumor and tumor-surrounding liver tissue of patients with HCC (n = 40, n = 10 treated with anti-PD-1 therapy). Phenotype, function and response to anti-PD-1 were analyzed by mass and flow cytometry ex vivo and in vitro, tissue residence was further assessed by immunohistochemistry and imaging mass cytometry. Gene signatures were analyzed in silico. We identified significant enrichment of heterogeneous populations of exhausted CD8+ T cells (TEX) in the tumor microenvironment. Strong enrichment of severely exhausted CD8 T cells expressing multiple immune checkpoints in addition to PD-1 was linked to poor progression-free and overall survival. In contrast, PD-1 was also expressed on a subset of more functional and metabolically active CD103+ tissue-resident memory T cells (TRM) that expressed few additional immune checkpoints and were associated with better survival. TEX enrichment was independent of BCLC stage, alpha-fetoprotein levels or age as a variable for progression-free survival in our cohort. These findings were in line with in silico gene signature analysis of HCC tumor transcriptomes from The Cancer Genome Atlas. A higher baseline TRM/TEX ratio was associated with disease control in anti-PD-1-treated patients. Our data provide information on the role of peripheral and intratumoral TEX-TRM dynamics in determining outcomes in patients with HCC. The dynamics between exhausted and liver-resident T cells have implications for immune-based diagnostics, rational patient selection and monitoring during HCC immunotherapies. The role of the immune response in hepatocellular carcinoma (HCC) remains unclear. T cells can mediate protection against tumor cells but are frequently dysfunctional and exhausted in cancer. We found that patients with a predominance of exhausted CD8+ T cells (TEX) had poor survival compared to patients with a predominance of tissue-resident memory T cells (TRM). This correlated with the molecular profile, metabolic and functional status of these cell populations. The enrichment of TEX was independently associated with prognosis in addition to disease stage, age and tumor markers. A high TRM proportion was also associated with better outcomes following checkpoint therapy. Thus, these T-cell populations are novel biomarkers with relevance in HCC.

Sections du résumé

BACKGROUND & AIMS
Despite recent translation of immunotherapies into clinical practice, the immunobiology of hepatocellular carcinoma (HCC), in particular the role and clinical relevance of exhausted and liver-resident T cells remain unclear. We therefore dissected the landscape of exhausted and resident T cell responses in the peripheral blood and tumor microenvironment of patients with HCC.
METHODS
Lymphocytes were isolated from the blood, tumor and tumor-surrounding liver tissue of patients with HCC (n = 40, n = 10 treated with anti-PD-1 therapy). Phenotype, function and response to anti-PD-1 were analyzed by mass and flow cytometry ex vivo and in vitro, tissue residence was further assessed by immunohistochemistry and imaging mass cytometry. Gene signatures were analyzed in silico.
RESULTS
We identified significant enrichment of heterogeneous populations of exhausted CD8+ T cells (TEX) in the tumor microenvironment. Strong enrichment of severely exhausted CD8 T cells expressing multiple immune checkpoints in addition to PD-1 was linked to poor progression-free and overall survival. In contrast, PD-1 was also expressed on a subset of more functional and metabolically active CD103+ tissue-resident memory T cells (TRM) that expressed few additional immune checkpoints and were associated with better survival. TEX enrichment was independent of BCLC stage, alpha-fetoprotein levels or age as a variable for progression-free survival in our cohort. These findings were in line with in silico gene signature analysis of HCC tumor transcriptomes from The Cancer Genome Atlas. A higher baseline TRM/TEX ratio was associated with disease control in anti-PD-1-treated patients.
CONCLUSION
Our data provide information on the role of peripheral and intratumoral TEX-TRM dynamics in determining outcomes in patients with HCC. The dynamics between exhausted and liver-resident T cells have implications for immune-based diagnostics, rational patient selection and monitoring during HCC immunotherapies.
LAY SUMMARY
The role of the immune response in hepatocellular carcinoma (HCC) remains unclear. T cells can mediate protection against tumor cells but are frequently dysfunctional and exhausted in cancer. We found that patients with a predominance of exhausted CD8+ T cells (TEX) had poor survival compared to patients with a predominance of tissue-resident memory T cells (TRM). This correlated with the molecular profile, metabolic and functional status of these cell populations. The enrichment of TEX was independently associated with prognosis in addition to disease stage, age and tumor markers. A high TRM proportion was also associated with better outcomes following checkpoint therapy. Thus, these T-cell populations are novel biomarkers with relevance in HCC.

Identifiants

pubmed: 35367533
pii: S0168-8278(22)00180-5
doi: 10.1016/j.jhep.2022.02.032
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

397-409

Informations de copyright

Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare no conflicts of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Auteurs

Maryam Barsch (M)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Henrike Salié (H)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Alexandra Emilia Schlaak (AE)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Zhen Zhang (Z)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Moritz Hess (M)

University Medical Center Freiburg, Institute for Medical Biometry and Statistics (IMBI), Germany.

Lena Sophie Mayer (LS)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Catrin Tauber (C)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Patricia Otto-Mora (P)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Takuya Ohtani (T)

University of Pennsylvania, Perelman School of Medicine, Institute for Immunology, USA.

Tobias Nilsson (T)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Lara Wischer (L)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Frances Winkler (F)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Sasikant Manne (S)

University of Pennsylvania, Perelman School of Medicine, Institute for Immunology, USA.

Andrew Rech (A)

University of Pennsylvania, Perelman School of Medicine, Institute for Immunology, USA.

Annette Schmitt-Graeff (A)

University Medical Center Freiburg, Institute of Clinical Pathology, Germany.

Peter Bronsert (P)

University Medical Center Freiburg, Institute of Clinical Pathology, Germany.

Maike Hofmann (M)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Christoph Neumann-Haefelin (C)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Tobias Boettler (T)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Stefan Fichtner-Feigl (S)

University Medical Center Freiburg, Clinic for General and Visceral Surgery, Germany.

Florian van Boemmel (F)

Leipzig University Medical Center, Division of Hepatology, Dpt. of Medicine II, Germany.

Thomas Berg (T)

Leipzig University Medical Center, Division of Hepatology, Dpt. of Medicine II, Germany.

Lorenza Rimassa (L)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Medical Oncology and Hematology Unit, Rozzano (Milan), Italy.

Luca Di Tommaso (L)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Pathology Unit IRCCS Humanitas Research Hospital Rozzano, Milan, Italy.

Anwaar Saeed (A)

Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, Kansas, USA.

Antonio D'Alessio (A)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Imperial College London, Faculty of Medicine, Department of Surgery & Cancer, UK.

David J Pinato (DJ)

Imperial College London, Faculty of Medicine, Department of Surgery & Cancer, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

Dominik Bettinger (D)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Harald Binder (H)

University Medical Center Freiburg, Institute for Medical Biometry and Statistics (IMBI), Germany.

E John Wherry (E)

University of Pennsylvania, Perelman School of Medicine, Institute for Immunology, USA.

Michael Schultheiss (M)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Robert Thimme (R)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany.

Bertram Bengsch (B)

University Medical Center Freiburg, Clinic for Internal Medicine II, Germany; University of Freiburg, Signalling Research Centres BIOSS and CIBSS, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany. Electronic address: bertram.bengsch@uniklinik-freiburg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH